EMERYVILLE, Calif., Dec. 27, 2022 /PRNewswire/ -- Amyris, Inc. (Nasdaq: AMRS), a leading synthetic biotechnology company accelerating the world's transition to sustainable consumption through its Lab-to-MarketTM technology platform today announced that it has completed the negotiation of key financial and business terms of the previously communicated strategic transaction for the exclusive rights to supply two of Amyris' ingredients.
Amyris (NASDAQ:AMRS) has hit a rough patch over the last two trading sessions as it is down 19% between last Thursday's close and Monday afternoon trading.
EMERYVILLE and CULVER CITY, Calif., January 3, 2022 — Amyris, Inc. (Nasdaq: AMRS), a leading synthetic biotechnology company accelerating the world to sustainable consumption through its Lab-to-MarketTM operating platform, and ImmunityBio (Nasdaq: IBRX), a clinical-stage immunotherapy company, today announced the completion of a previously announced joint venture agreement to accelerate the commercialization of a leading next-generation COVID-19 vaccine.
EMERYVILLE, Calif., Aug. 24, 2021 /PRNewswire/ -- Amyris, Inc., (Nasdaq: AMRS), a leading synthetic biotechnology company in Clean Health and Beauty markets through its consumer brands and a top supplier of sustainable and natural ingredients, today announced that it closed the acquisitions of OLIKA, Inc. (OLIKA), an award-winning clean consumer brand, and MG Empower Ltd., a leading global influencer marketing agency on August 11.
EMERYVILLE, Calif., Aug. 20, 2021 /PRNewswire/ -- Amyris, Inc. (Nasdaq: AMRS), a leading synthetic biotechnology company active in the Clean Health and Beauty markets through its consumer brands, and a top supplier of sustainable and natural ingredients, today announced promising in-vivo results in a study of its licensed RNA vaccine through intranasal delivery, developed in collaboration with the Infectious Disease Research Institute (IDRI).
EMERYVILLE, Calif., April 15, 2021 /PRNewswire/ -- Amyris, Inc., (Nasdaq: AMRS), a leading synthetic biotechnology company active in the Clean Health and Beauty markets through its consumer brands and a top supplier of sustainable and natural ingredients, today announced that it has executed a binding term sheet for the acquisition of Gen Z-focused beauty brand, EcoFabulous Cosmetics (EcoFabulous). The acquisition furthers Amyris's growth and market leadership in clean beauty and complements Amyris's family of consumer brands, consisting of Biossance®, Pipette®, Rose Inc., JVN, Terasana, and Costa Brazil.
EMERYVILLE, Calif., March 1, 2021 /PRNewswire/ -- Amyris, Inc., (Nasdaq: AMRS), a leading synthetic biotechnology company active in the Clean Health and Beauty markets through its consumer brands and a top supplier of sustainable and natural ingredients, announces that it has entered into an agreement to acquire Costa Brazil. Amyris is accelerating its growth and market leadership in clean beauty with the addition of Costa Brazil to its family of consumer brands, including Biossance®, Pipette®, Rose Inc., JVN, and Terasana.
Biotechnology company Amyris has reported positive preliminary results in a pre-clinical study of its ribonucleic acid (RNA) vaccine platform for treating Covid-19.
DSM Takes Stake in Amyris